BioDelivery Sciences International, Inc. Sustainability Profile
BioDelivery Sciences International, Inc. (BDSI), headquartered in the United States, is a pioneering biopharmaceutical company focused on developing and commercialising innovative therapeutics for patients with chronic pain and substance use disorders. Founded in 1997, BDSI has achieved significant milestones, including the successful launch of its flagship product, BELBUCA®, a buprenorphine film that offers a unique delivery system for pain management. Operating primarily in the biopharmaceutical industry, BDSI is dedicated to advancing its proprietary drug delivery technologies, which enhance the efficacy and safety of its products. With a strong market position, BDSI has garnered recognition for its commitment to improving patient outcomes and addressing unmet medical needs. The company continues to expand its portfolio, solidifying its role as a leader in the field of pain management and addiction treatment.
DitchCarbon Score
How does BioDelivery Sciences International, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BioDelivery Sciences International, Inc.'s score of 25 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
BioDelivery Sciences International, Inc.'s reported carbon emissions
BioDelivery Sciences International, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Collegium Pharmaceutical, Inc., which may influence its climate-related initiatives and reporting. As of now, BioDelivery Sciences has not established any documented reduction targets or commitments to the Science Based Targets initiative (SBTi). The lack of specific climate pledges or reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the context of the pharmaceutical industry, where sustainability and carbon footprint reduction are increasingly important, BioDelivery Sciences may benefit from aligning its practices with industry standards and expectations. This could involve setting measurable targets for emissions reduction and participating in initiatives that promote environmental responsibility.
How Carbon Intensive is BioDelivery Sciences International, Inc.'s Industry?
How Carbon Intensive is BioDelivery Sciences International, Inc.'s Location?
BioDelivery Sciences International, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
BioDelivery Sciences International, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
